Celestica Just Unloaded Bad News

Celestica (CLS) delivered strong Q2 CY26 results, with accelerating AI networking switch revenue and significant gross margin expansion. The company is funding growth with a $1B capex program and a recent $3B equity offering, which is expected to be dilutive short-term by ~8.4–10%, but is positioned to enhance margin resilience. Overall, hyperscaler-driven demand plus margin improvement and the growth capex plan point to sustained high growth despite near-term dilution.

Analysis

CLS is emerging as a scarce-capacity proxy for the AI networking buildout, and that scarcity is the real earnings lever: when a supplier can pre-secure materials and add capacity into a bottlenecked customer demand curve, incremental revenue tends to arrive with operating leverage rather than the reverse. The market should distinguish between the dilution from the equity raise and the longer-dated equity value created if management is correctly front-loading capex into a multi-quarter supply shortage; in that case, the financing is less a reset than a bridge to a larger revenue base.

Second-order effects matter. If CLS is taking meaningful share in AI switching, peers with less willingness to fund capacity or weaker supplier relationships could lose sockets, especially other EMS/ODM names that lack the same hyperscaler pull-through. At the same time, the pre-buy of raw materials is a double-edged sword: it supports margin resilience if volumes stay hot, but it increases inventory and working-capital risk if customer build plans normalize, which would show up first in cash conversion before it hits the P&L.

The contrarian view is that consensus may be extrapolating one strong quarter into a durable step-function in earnings power while underweighting the cyclicality of networking supply chains. The most important reversal signal over the next 1-3 months would be any slowdown in sequential AI networking revenue growth or a guide that implies capex is outrunning backlog conversion. Over 6-18 months, the stock works only if margin expansion persists after the initial capacity catch-up; if not, the market will re-rate it back toward a lower-multiple contract manufacturing name despite the AI label.

Key Decisions for Investors

• Buy CLS on post-offering weakness rather than chase strength; use the equity raise overhang as the entry point and underwrite a 6-12 month thesis, not a one-quarter trade. Risk/reward is attractive only if the next guide confirms sequential AI networking acceleration.
• Pair trade: long CLS / short a broader industrial or EMS proxy with weaker AI exposure (e.g., Jabil or Flex) if CLS continues to show superior margin expansion and backlog conversion. This expresses relative share gains in AI networking rather than a naked multiple bet.
• If CLS is already extended, use call spreads instead of outright shares to capture the capex-to-growth inflection while limiting dilution/working-capital downside. Best tenor is 3-6 months, keyed to the next two earnings prints.
• Set a watch item on cash conversion and inventory days: if working capital expands faster than revenue for two consecutive quarters, reduce exposure. That would be the first falsifier of the 'capacity investment creates durable ROIC' thesis.
• For longer-term investors, add only if management reiterates capex discipline and gross margin stays structurally above prior-cycle levels; if gross margin reverts or AI networking growth decelerates, exit rather than average down.